Genmab

This early-stage trial tested a new drug called GEN1078 in people with advanced solid cancers that had stopped responding to standard treatments. The main goals were to check the drug's safety, see how the body processes it, and get a first look at whether it might help shrink tu…

This early-stage trial tested whether combining a new drug called GEN1042 with radiation therapy, with or without another immunotherapy drug (pembrolizumab), is safe and can help shrink tumors in people with advanced solid cancers that have spread. The study was for adults whose …

This study tested a new antibody drug called GEN3014 in people with multiple myeloma and other blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug showed early signs of helping control the cance…

This early-stage trial tested a new drug called GEN3017, given as an injection under the skin, for people with advanced Hodgkin and Non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goals were to find a safe dose and see how the body hand…

This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The s…

This early-stage trial tested a new cancer drug called GEN1055, both alone and combined with an existing immunotherapy drug (pembrolizumab), for people with advanced solid tumors. The study aimed to find safe doses and see if the treatment could shrink tumors. The trial was termi…

This early-stage study tested a new drug called PRO1160 in 42 patients with advanced cancers that had spread or returned after previous treatments. The main goals were to find a safe dose and see if the drug could help control kidney cancer, nasopharyngeal cancer, or lymphoma. Th…